Cadila Healthcare Ltd has received approval from the US FDA to market Ribavirin Capsules, 200 mg, an anti-viral drug, in the US market. Following this, the group plans to launch the drug in December this year. The current sales of Ribavirin Capsules (200 mg) in the US market as per IMS is estimated at USD 341 million, stated a company release.

The approval for Ribavirin Capsules is the latest in a series of developments that mark the company's foray in the US generic markets. So far the group has received 8 ANDA approvals. The group launched Atenolol and Metformin in the US market, early this year through its US subsidiary Zydus Pharmaceuticals USA Inc.

The process of filing ANDAs began in 2003-04 with the group filing 12 ANDAs, the largest number filed by an Indian company in the very first year of filing. Till date, the group has filed 28 ANDAs and 34 DMFs, added the release.